<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04927715</url>
  </required_header>
  <id_info>
    <org_study_id>Soh-Med-21-02-26</org_study_id>
    <nct_id>NCT04927715</nct_id>
  </id_info>
  <brief_title>Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.</brief_title>
  <official_title>FDNC5 Genetic Polymorphism in Patients With Peripartum Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sohag University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sohag University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      this is an observertional study aimed at Study the association between the level of irisin&#xD;
      expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism in female&#xD;
      patients with peripartum cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Irisin level</measure>
    <time_frame>4 months</time_frame>
    <description>detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FNDC5 Genotyping</measure>
    <time_frame>4 months</time_frame>
    <description>whether homogenetic or heterogenetic</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Peripartum Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Diseased</arm_group_label>
    <description>Females with peripartum cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy females</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        females who have been diagnosed and treated clinically for peripartum cardiomyopathy in our&#xD;
        center in sohag university hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  This study will include females aged between 18 and 45 years old who have been&#xD;
             diagnosed and treated clinically for peripartum cardiomyopathy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 or more than 45 year old&#xD;
&#xD;
          -  females with dilated cardiomyopathy due to other etiology or outside the time frame of&#xD;
             occurrence of peripartum cardiomyopathy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>the studied disease peripartum cardiomyopathy is female specific</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ali mo Altaher, lecturer</last_name>
    <phone>01003376529</phone>
    <phone_ext>+20</phone_ext>
    <email>dr.ali.altaher30@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sohag uniersity hosoital</name>
      <address>
        <city>Sohag</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali mo Altaher, lecturer</last_name>
      <phone>01003376529</phone>
      <phone_ext>+20</phone_ext>
      <email>dr.ali.altaher30@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 9, 2021</study_first_submitted>
  <study_first_submitted_qc>June 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sohag University</investigator_affiliation>
    <investigator_full_name>Ali Mohamed Ahmed Altaher</investigator_full_name>
    <investigator_title>clinical professor</investigator_title>
  </responsible_party>
  <keyword>Peripartum Cardiomyopathy, Irisin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

